Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

We recently published a list of 10 Best Stocks to Invest in for Long Term. In this article, we are going to take a look at ...

Owned by Vietnam’s wealthiest man, VinFast is more immune to not making a profit. On Thursday, the company reported it lost ...

Zepbound (tirzepatide) is a weekly injectable weight-loss medication. It can be purchased online or in person with a valid ...

Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Long a lobbying powerhouse in Washington, pharma’s struggling to settle on a strategy for defending itself, according to six industry lobbyists and three company officials who spoke to POLITICO. All ...

Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ratings for the ...

Eleven Madison Park leads the plant-based culinary revolution, Le Poisson Rouge paves the way for indie music, and Air Company reimagines the future of fuel ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Shares in pharmaceuticals firm Eli Lilly (LLY) rose today after it said it was suing companies ripping off its weight-loss ...

Senior Health Correspondent for TIME, Alice Park, gives us a deeper look into how Eli Lilly's new pill orforglipron may ...